Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

In the complaints, Lilly alleges that the telemedicine companies are marketing tirzepatide mixed with substances such as glycine, l-arginine, niacinamide, and pyridoxine. These additives are not ...

The efficacy and safety of tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, in patients with MASH and moderate or severe fibrosis ...

Adults receiving tirzepatide lost more weight and had a greater decline in waist circumference than those receiving semaglutide. The proportion of adults experiencing adverse events was similar in ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Tirzepatide discontinuation was associated with reduced cardiometabolic benefits especially among patients with body weight ...

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from Mounjaro. The Food and Drug Administration (FDA) does not regulate the ...

In SURMOUNT-1, adults with prediabetes receiving tirzepatide were 94% less likely to develop type 2 diabetes than placebo at 176 weeks. Those receiving 15 mg tirzepatide lost 22.9% of their body ...

Each participant received weekly doses of tirzepatide—either 5 mg, 10 mg, or 15 mg—for three years. At the end of this period, the results were impressive. On average, participants lost ...

Both are chronic conditions that progressively worsen over time. Tirzepatide targets two receptors in order to shrink fat cells and reduce the impacts that enlarged fat cells have on heart and ...